These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 19789013)

  • 21. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT).
    Vu-Nishino H; Tavassoli FA; Ahrens WA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1040-7. PubMed ID: 15990007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma.
    Imamura H; Haga S; Shimizu T; Watanabe O; Kajiwara T; Aiba M
    Br J Cancer; 1999 Jan; 79(1):172-8. PubMed ID: 10408711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer.
    Kruper L; Xu X; Henderson K; Bernstein L
    Ann Surg Oncol; 2011 Oct; 18(11):3210-9. PubMed ID: 21863363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
    Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
    Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in quantitative nuclear features between ductal carcinoma in situ (DCIS) with and without accompanying invasive carcinoma in the surrounding breast.
    Susnik B; Worth A; Palcic B; Poulin N; LeRiche J
    Anal Cell Pathol; 1995 Jan; 8(1):39-52. PubMed ID: 7734410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ.
    Patla A; Rudnicka-Sosin L; Pawlega J; Stachura J
    Pol J Pathol; 2002; 53(1):25-7. PubMed ID: 12014222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.
    Asjoe FT; Altintas S; Huizing MT; Colpaert C; Marck EV; Vermorken JB; Tjalma WA
    Breast J; 2007; 13(4):359-67. PubMed ID: 17593040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancer.
    Gold HT; Do HT; Dick AW
    Cancer; 2008 Dec; 113(11):3108-15. PubMed ID: 18932243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase activity in ductal carcinoma in situ and invasive breast cancer.
    Umbricht CB; Sherman ME; Dome J; Carey LA; Marks J; Kim N; Sukumar S
    Oncogene; 1999 Jun; 18(22):3407-14. PubMed ID: 10362362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.
    Fisher ER; Land SR; Saad RS; Fisher B; Wickerham DL; Wang M; Costantino JP; Wolmark N
    Am J Clin Pathol; 2007 Jul; 128(1):86-91. PubMed ID: 17580274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of large sections on the study of in situ and invasive duct carcinoma of the breast.
    Foschini MP; Flamminio F; Miglio R; Calò DG; Cucchi MC; Masetti R; Eusebi V
    Hum Pathol; 2007 Dec; 38(12):1736-43. PubMed ID: 17714759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal breast cancer: evaluation of histology and biological marker expression.
    Dublin EA; Millis RR; Smith P; Bobrow LG
    Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy.
    Jobsen JJ; Van Der Palen J; Ong F; Meerwaldt JH
    Acta Oncol; 2007; 46(2):172-80. PubMed ID: 17453365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting successful breast conservation for ductal carcinoma in situ.
    Dillon MF; Mc Dermott EW; O'Doherty A; Quinn CM; Hill AD; O'Higgins N
    Ann Surg Oncol; 2007 May; 14(5):1618-28. PubMed ID: 17443388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.
    Rutstein LA; Johnson RR; Poller WR; Dabbs D; Groblewski J; Rakitt T; Tsung A; Kirchner T; Sumkin J; Keenan D; Soran A; Ahrendt G; Falk JS
    Breast J; 2007; 13(3):251-7. PubMed ID: 17461899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.